tiprankstipranks
Chromocell Therapeutics Corp (CHRO)
NYSE MKT:CHRO
US Market

Chromocell Therapeutics Corp (CHRO) Stock Price & Analysis

8 Followers

CHRO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.06 - $6.00
Previous Close$1.17
Volume11.93K
Average Volume (3M)18.49K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$96.39K
Total Debt (Recent Filing)$1.27M
Price to Earnings (P/E)
Beta2.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding5,766,704
10 Day Avg. Volume22,139
30 Day Avg. Volume18,491
Standard Deviation0.03
R-Squared0.59
Alpha-0.30
Financial Highlights & Ratios
Price to Book (P/B)-1.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Ownership Overview

18.47%0.00%4.37%77.16%
18.47% Insiders
4.37% Other Institutional Investors
77.16% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

CHRO FAQ

What was Chromocell Therapeutics Corp’s price range in the past 12 months?
Chromocell Therapeutics Corp lowest stock price was $1.06 and its highest was $6.00 in the past 12 months.
    What is Chromocell Therapeutics Corp’s market cap?
    Currently, no data Available
    When is Chromocell Therapeutics Corp’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Chromocell Therapeutics Corp’s earnings last quarter?
    Currently, no data Available
    Is Chromocell Therapeutics Corp overvalued?
    According to Wall Street analysts Chromocell Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Chromocell Therapeutics Corp pay dividends?
      Chromocell Therapeutics Corp does not currently pay dividends.
      What is Chromocell Therapeutics Corp’s EPS estimate?
      Chromocell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Chromocell Therapeutics Corp have?
      Chromocell Therapeutics Corp has 5,766,704 shares outstanding.
        What happened to Chromocell Therapeutics Corp’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Chromocell Therapeutics Corp?
        Currently, no hedge funds are holding shares in CHRO
        ---

        Chromocell Therapeutics Corp Stock Smart Score

        10
        Unlock Smart Score
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Fundamentals

        Return on Equity
        Trailing 12-Months
        Asset Growth
        8194.02%
        Trailing 12-Months

        Company Description

        Chromocell Therapeutics Corp

        Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
        ---

        CHRO Stock 12 Month Forecast

        Average Price Target

        $8.50
        ▲(614.29% Upside)
        {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$8.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Feb<br/>2024","9":"May<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.7892307692307692,2.3484615384615384,2.9076923076923076,3.4669230769230768,4.026153846153846,4.585384615384616,5.144615384615385,5.703846153846154,6.263076923076923,6.822307692307692,7.381538461538462,7.940769230769231,{"y":8.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.7892307692307692,2.3484615384615384,2.9076923076923076,3.4669230769230768,4.026153846153846,4.585384615384616,5.144615384615385,5.703846153846154,6.263076923076923,6.822307692307692,7.381538461538462,7.940769230769231,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.7892307692307692,2.3484615384615384,2.9076923076923076,3.4669230769230768,4.026153846153846,4.585384615384616,5.144615384615385,5.703846153846154,6.263076923076923,6.822307692307692,7.381538461538462,7.940769230769231,{"y":8.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.8,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.8,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.65,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.39,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.77,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.34,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.37,"date":1718928000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

        Best Analysts Covering CHRO

        1 Year
        James MolloyAlliance Global Partners
        1 Year Success Rate
        0/1 ratings generated profit
        0%
        1 Year Average Return
        -17.60%
        initiated a buy rating 30 days ago
        Copying James Molloy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -17.60% per trade.
        Popular Stocks
        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis